American Heart Association

Half of patients denied insurance coverage of new cholesterol drugs

By AMERICAN HEART ASSOCIATION NEWS

A pair of cholesterol-lowering drugs called PCSK9 inhibitors were controversial as soon as they hit the market in 2015. They cost an average $14,300 a year, and prescriptions require prior authorization by health insurance companies — which a new study shows isn’t a guarantee.

Only 47 […]

October 30th, 2017|Categories: Cholesterol, Health, Patients, Research|Tags: , , , , , |Comments Off on Half of patients denied insurance coverage of new cholesterol drugs

Pricey cholesterol drug cuts heart attack, stroke risk

By AMERICAN HEART ASSOCIATION NEWS

A highly anticipated study has found that the new cholesterol-lowering drug evolocumab can reduce heart attacks and strokes among high-risk patients.

The findings, published last week in the New England Journal of Medicine and presented at the American College of Cardiology’s annual meeting, showed that the […]

New drugs slash bad cholesterol

By AMERICAN HEART ASSOCIATION NEWS

Editor’s note: This is one in a 10-part series of the top medical research advances in 2015 as determined by American Heart Association volunteer and staff leaders.

The blockbuster drugs known as statins are teaming with a new medication to lower the level of bad LDL […]

Powerful cholesterol drug awaits FDA’s decision

By AMERICAN HEART ASSOCIATION NEWS

A second in a new class of drugs that sharply lowers cholesterol is set for federal approval by Thursday – a “game-changer” for the hardest-to-treat patients who are in danger of heart attacks and strokes.

For people with familial hypercholesterolemia, or FH, a genetic condition that […]

August 26th, 2015|Categories: Health|Tags: , , , |Comments Off on Powerful cholesterol drug awaits FDA’s decision